-

Elanco Launches Product for U.S. Poultry Producers, Providing a Flexible Option for Cocci Control

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) launches ZoaShield™ in the United States, which offers poultry producers a proven and flexible zoalene solution that keeps coccidiosis under control in an easy, manageable way.

A critical component of maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks, is having a reliable, efficacious anticoccidial program. ZoaShield offers producers a flexible, proven active ingredient product that can be used in a variety of seasons and operations.

“Producers know and trust zoalene as an anticoccidial option,” said Andrew Carlson, executive director of U.S. Poultry and Nutritional Health at Elanco. “ZoaShield provides the reliability producers have come to expect to help manage coccidiosis in their flock while at the same time providing flexibility for their type of operation.”

When producers use ZoaShield or any of the Elanco intestinal integrity products, they receive consultative support from Elanco field experts who have extensive industry experience and knowledge, allowing them to tailor solutions to all types of poultry operations.

“Elanco equips producers with a wide range of tools they can use to prevent, treat and control common poultry challenges in order to keep their operations running smoothly,” said Carlson.

To find out more about ZoaShield and other poultry products and services, visit us online.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

ZoaShield, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2021 Elanco or its affiliates. PM-US-21-0752

Contacts

Investor Contact: Tiffany Kanaga +1.302.897.0668 Tiffany.Kanaga@elancoah.com
Media Contact: Sarah Morehouse +1.317.914.7568 Sarah.Morehouse@network.elancoah.com

Elanco Animal Health Incorporated

NYSE:ELAN

Release Versions

Contacts

Investor Contact: Tiffany Kanaga +1.302.897.0668 Tiffany.Kanaga@elancoah.com
Media Contact: Sarah Morehouse +1.317.914.7568 Sarah.Morehouse@network.elancoah.com

More News From Elanco Animal Health Incorporated

Elanco to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-10, 2024. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts on Tuesday, January 9, 2024 at 3:00 p.m. PST (6:00 PM EST). A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days....

Elanco to Participate in Evercore ISI 6th Annual HealthCONx Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Evercore ISI 6th Annual HealthCONx Conference, November 28-29, 2023. Todd Young, Executive Vice President and CFO, will participate in a fireside chat on Wednesday, November 29 at 8:20 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorpor...

Elanco Animal Health Reports Third Quarter 2023 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2023, provided guidance for the fourth quarter of 2023, and updated guidance for the full year 2023. “Elanco delivered a strong third quarter across both pet health and farm animal, with revenue, adjusted EBITDA, and adjusted EPS growth. Constant currency revenue growth of 5 percent was driven by accelerating contribution from innovation, stabilizing core v...
Back to Newsroom